Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children (6 to \< 12 years of age and/or weighing 17.5 to \< 35 Kg).~* Chronic HCV genotype 4 infection for at least 6 months without cirrhosis (confirmed by Fibroscan).~* Naïve patients to previous anti-HCV treatment.~* Diagnosed with hematological malignancy and on maintenance chemotherapy.~Exclusion Criteria:~* Known hypersensitivity to any of the study medications.~* Ongoing treatment with any interacting medications like carbamazepine, fosphenytoin, phenytoin, oxcarbazepine, phenobarbital, and rifampin.~* History of any comorbid illness that may interfere with the pharmacokinetics of the study drugs or prohibit the compliance with the study protocol such as;~  1. Decompensated liver disease as shown by the presence of ascites, encephalopathy, or a history of variceal hemorrhage.~ 2. The ongoing treatment of other types of cancer or blood disorders.~ 3. Co-infection with human immunodeficiency virus (HIV), or hepatitis B virus.~ 4. Renal dysfunction.~ 5. Active infection that is currently producing symptoms.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- HCV-infected patients with hematological malignancy (Type: ACTIVE_COMPARATOR): HCV-infected patients with hematological malignancy on maintenance chemotherapy
- Control HCV-infected patients (Type: ACTIVE_COMPARATOR): Control HCV-infected patients without haematological malignancy or co-morbidities.

Based on this trial design, predict the completion outcome and termination type (if applicable).